Q-omics provides the consensus-scored TEKT1 profile across patient tissues and cancer cell-line models. TEKT1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TEKT1 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, TEKT1 RNA expression shows 12,194 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, LUSC, and TGCT as cancer lineages where TEKT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEKT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEKT1 survival associations across molecular data types. TEKT1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEKT1 RNA expression–survival associations across cancer types. High TEKT1 expression shows unfavorable associations in THCA, LGG and DLBC, but favorable associations in CESC, UCEC and CHOL. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for TEKT1 RNA expression.
This table summarizes TEKT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TEKT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEKT1 shows lower tumor expression in LUSC, LUAD, KIRC, KICH and THCA and higher tumor expression in LIHC. The LUSC box plot shows higher TEKT1 RNA expression in normal versus tumor tissue (log2 FC = −3.087, t-test p < 0.001).
This table shows molecular features associated with TEKT1 in patient tissues and cancer cell lines. In patient samples, TEKT1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TEKT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
